Active Ingredient History

  • Now
Dromostanolone Propionate (known by the brand names Masteron and Drolban) was invented by Syntex in 1959. About 10 years later it was released on the American market by Lilly as brand name Drolban. The drug was first approved in the USA for use as a treatment of female breast cancer. However, the profile of side-effects included pronouncement of male characteristics in women and when more effective breast cancer treatments came to market drostanolone was gradually phased out. No longer used clinically dromostanolone propionate became very popular in the bodybuilding community. Today dromostanolone propionate remains on the list of approved medications, but it is not being manufactured or sold by pharmaceutical companies. It is still produced illegally by underground labs for use in the bodybuilding community.   NCATS

  • SMILES: C[C@@H]1C[C@@]2(C)[C@@H](CC[C@H]3[C@@H]4CC[C@H](O)[C@@]4(C)CC[C@H]23)CC1=O
  • Mol. Mass: 304.4669
  • ALogP: 5.17
  • ChEMBL Molecule:
More Chemistry
  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Discontinued
  • Delivery Methods: Parenteral
  • Pro Drug: Yes
17 beta-hydroxy-2 alpha-methyl-5 alpha-androstan-3-one | 17beta-hydroxy-2alpha-methyl-5alpha-androstan-3-one | 2alpha-methyldihydrotestosterone | 2 alpha-methyldihydrotestosterone propionate | 32379 | dihydro-2alpha-methyltestosterone | drolban | dromostanolone | dromostanolone, (5alpha,17beta)-isomer | dromostanolone propionate | drostanolon | drostanolona | drostanolone | drostanolone propionate | drostanolonum | emdisterone | masteril | masterone | medrosteron | medrotestron | medrotestrone propanoate | medrotestrone propionate | medrotestron propionate | methalone | metholone | nsc 12198 | nsc-12198 | permastril | prometholone


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue